Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    21376385 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
Conditions: Metastatic Breast Cancer;   Toxicity;   Neurotoxicity;   Drug Toxicity;   Adverse Drug Event
Intervention: Drug: ERIBULIN MESYLATE
2 Active, not recruiting Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: low-dose-bevacizumab/pemetrexed;   Drug: Treatment of physician's choice
3 Recruiting Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Conditions: Metastatic Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention: Drug: Bevacizumab and eribulin
4 Completed
Has Results
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: E7389;   Drug: Physician's Choice

Indicates status has not been verified in more than two years